Dabrafenib is an investigational drug that works by inhibiting the activity of BRAF, a protein which, when mutated, drives the growth of many melanomas. Prior research has shown that dabrafenib is more effective than standard chemotherapy for slowing the growth of inoperable stage III or IV melanoma. It is a pill that it taken orally (by mouth).
In this study, researchers are evaluating the safety and effectiveness of dabrafenib in patients with stage IIIC melanoma that was able to be surgically removed and contains a BRAF V600 mutation. Even after surgery, people with stage IIIC melanoma have a high risk of disease recurrence, and doctors are hoping that dabrafenib can reduce this risk.